Helicobacter pylori erradication in end stage renal disease

comparison of 14 days hybrid therapy with 14 days standard triple therapy on erradication of H.pylori in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307221241N4

Enrollment

Registered

2014-11-13

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Other specified bacterial agents as the cause of diseases classified to other chapters

Interventions

Intervention 1: standard triple therapy include : pantoprazole 40 mg BID + Amoxicilline 500 mg BID +Clarithromycine 500 mg BID for 14 days. Intervention 2: hybrid regimen include :pantoprazole 40 mg B

Treatment - Drugs

standard triple therapy include : pantoprazole 40 mg BID + Amoxicilline 500 mg BID +Clarithromycine 500 mg BID for 14 days

hybrid regimen include :pantoprazole 40 mg BID + Amoxicilline 500 mg BID for 14 days + tinidazole 500 mg BID + Clarithromycine 500 mg BID for second 7 days.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: 18 - 80 years patients on hemodialysis for at least 3 months who have GI symptoms such as dyspepsia or epigasteric pain , or referred for evaluation of H.pylori infection before renal transplantation , or for evaluation of Iron Defficiency Anemia , endoscopy has done and H.pylori confirmed by at least one positive test out of the following : rapid urease test (RUT) ,or histology , or stool antigen test . Exclusion criteria : -age less than 18 yr and more than 80 yr . -advanced chronic disease or any other pathology that prevents attending controls and fallow up . -allergy to any of the antibiotics in the treatment . -previous gastric surgery -pregnancy and lactation -previous eradication treatment consumption of antibiotics or bismuth salts during the last 4 weeks . - concurrent use of anticoagulant or ketoconazole and or steroids -severe heart failure include myocardial infarction or EF < 30 that confirmed by echocardiogram -incooperative pationt

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori infection. Timepoint: begining of study. Method of measurement: rapid urease test and biopsy and stool h.pylori antigen test in begining of study.	—

Secondary

Measure	Time frame
H.pylori eradication. Timepoint: 8 weeks after treatment. Method of measurement: stool h.pylori antigen test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Atie Makhlough

Mazandaran University of Medical Science and Health Services

makhlough_a@yahoo.com+98 15 1226 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026